Cargando…

Association between control group therapy and magnitude of clinical benefit of cancer drugs

Little is known about the impact of control group therapy on clinical benefit scales such as American Society of Clinical Oncology Value Framework (ASCO-VF), European Society for Medical Oncology Magnitude Clinical Benefit Scale (ESMO-MCBS), National Comprehensive Cancer Network (NCCN) Evidence Bloc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Molto, Consolacion, Tibau, Ariadna, Bujosa, Aida, Tapia, Jose Carlos, Mittal, Abhenil, Tamimi, Faris, Amir, Eitan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9734169/ https://www.ncbi.nlm.nih.gov/pubmed/36494465 http://dx.doi.org/10.1038/s41598-022-25983-9

Ejemplares similares

Clinical benefit of cancer drugs approved in Switzerland 2010–2019
por: Adam, Roman, et al.
Publicado: (2022)

Utility of ctDNA in predicting relapse in solid tumors after curative therapy: a meta-analysis
por: Mittal, Abhenil, et al.
Publicado: (2023)

Changes in circulating tumor DNA and outcomes in solid tumors treated with immune checkpoint inhibitors: a systematic review
por: Al-Showbaki, Laith, et al.
Publicado: (2023)

Filling the Gap after CDK4/6 Inhibitors: Novel Endocrine and Biologic Treatment Options for Metastatic Hormone Receptor Positive Breast Cancer
por: Mittal, Abhenil, et al.
Publicado: (2023)

Prognostic value of human leukocyte antigen G expression in solid tumors: a systematic review and meta-analysis
por: Bartolome, Jorge, et al.
Publicado: (2023)

Combining PARP inhibitors and platinum-based chemotherapy in metastatic triple negative and/or BRCA-associated breast cancer
por: Molto Valiente, Consolacion, et al.
Publicado: (2023)

Role of cooperative groups and funding source in clinical trials supporting guidelines for systemic therapy of breast cancer
por: Tibau, Ariadna, et al.
Publicado: (2018)

Fragility of randomized trials supporting cancer drug approvals stratified by approval pathway and review designations
por: Wilson, Brooke E., et al.
Publicado: (2021)

Clinical Benefit and Expedited Approval of Cancer Drugs in the United States, European Union, Switzerland, Japan, Canada, and Australia
por: Hwang, Thomas J., et al.
Publicado: (2022)

ESMO-Magnitude of Clinical Benefit Scale (MCBS) group
por: Amaral, Teresa
Publicado: (2019)

Extended Adjuvant Tamoxifen for Early Breast Cancer: A Meta-Analysis
por: Al-Mubarak, Mustafa, et al.
Publicado: (2014)

ASO Author Reflections: Germline Testing for All Patients With Breast Cancer: Has the Time Finally Come?
por: Mittal, Abhenil, et al.
Publicado: (2021)

Triplet Therapy in Metastatic Castrate Sensitive Prostate Cancer (mCSPC)—A Potential New Standard of Care
por: Mittal, Abhenil, et al.
Publicado: (2023)

Twelve years of European cancer drug approval—a systematic investigation of the ‘magnitude of clinical benefit’
por: Grössmann, N., et al.
Publicado: (2021)

Isolated central nervous system relapse of multiple myeloma post autologous stem cell transplant- A rare presentation
por: Mittal, Abhenil, et al.
Publicado: (2020)

Interaction between Hormonal Receptor Status, Age and Survival in Patients with BRCA1/2 Germline Mutations: A Systematic Review and Meta-Regression
por: Templeton, Arnoud J., et al.
Publicado: (2016)

Applying the ESMO-Magnitude of Clinical Benefit Scale in real life
por: Ciardiello, Fortunato, et al.
Publicado: (2016)

Comparing Lifestyle Modifications and the Magnitude of Their Associated Benefit on Cancer Mortality
por: Dougherty, Timothy P., et al.
Publicado: (2023)

Magnitude of Drug–Drug Interactions in Special Populations
por: Bettonte, Sara, et al.
Publicado: (2022)

Shortened treatment regimens versus the standard regimen for drug‐sensitive pulmonary tuberculosis
por: Grace, Angeline G, et al.
Publicado: (2019)

Letter comments on: “Twelve years of European cancer drug approval—a systematic investigation of the ‘magnitude of clinical benefit’”
por: Müller, B., et al.
Publicado: (2022)

Individual differences in working memory capacity are unrelated to the magnitudes of retrocue benefits
por: Ye, Chaoxiong, et al.
Publicado: (2021)

Application of the ESMO-Magnitude of Clinical Benefit Scale (V.1.1) to the field of early breast cancer therapies
por: Paluch-Shimon, Shani, et al.
Publicado: (2020)

Outcome Probability versus Magnitude: When Waiting Benefits One at the Cost of the Other
por: Young, Michael E., et al.
Publicado: (2014)

ESMO - Magnitude of Clinical Benefit Scale V.1.0 questions and answers
por: Cherny, N I, et al.
Publicado: (2016)

The magnitude of the survival benefit of internal thoracic artery grafting: Absolute risk reduction
por: Ohno, Takayuki
Publicado: (2021)

Essential cancer medicines: adding feasibility to the magnitude of clinical benefit value chain
por: Roitberg, F., et al.
Publicado: (2023)

Magnitude of drug resistant shigellosis in Nepalese patients
por: Khan, Salman, et al.
Publicado: (2013)

Anticancer drugs approved by the Food and Drug Administration for gastrointestinal malignancies: Clinical benefit and price considerations
por: Jiang, Di Maria, et al.
Publicado: (2019)

Near-complete response to low-dose ceritinib in recurrent infantile inflammatory myofibroblastic tumour
por: Mittal, Abhenil, et al.
Publicado: (2021)

Recurrent infantile inflammatory myofibroblastic tumor of mesentery––Case report and review of imaging findings
por: Gupta, Aarushi, et al.
Publicado: (2020)

Near-complete response to low-dose ceritinib in recurrent infantile inflammatory myofibroblastic tumour
por: Mittal, Abhenil, et al.
Publicado: (2021)

Impact of Value Frameworks on the Magnitude of Clinical Benefit: Evaluating a Decade of Randomized Trials for Systemic Therapy in Solid Malignancies
por: Cusano, Ellen, et al.
Publicado: (2021)

Treatment with anticancer drugs for advanced pancreatic cancer: a systematic review
por: Salazar, Josefina, et al.
Publicado: (2023)

Magnitude and determinants of energy intensity: evidence from Indian firms
por: Kumar, Aman, et al.
Publicado: (2022)

Are Quality of Randomized Clinical Trials and ESMO-Magnitude of Clinical Benefit Scale Two Sides of the Same Coin, to Grade Recommendations for Drug Approval?
por: Rodriguez, Adela, et al.
Publicado: (2021)

High degree of fluoroquinolone resistance among pulmonary tuberculosis patients in New Delhi, India
por: Sharma, Rohini, et al.
Publicado: (2019)

Imaging and Pathological Features of Alveolar Soft Part Sarcoma: Analysis of 16 Patients
por: Gulati, Malvika, et al.
Publicado: (2021)

Electrospun Nanofibers: Recent Applications in Drug Delivery and Cancer Therapy
por: Contreras-Cáceres, Rafael, et al.
Publicado: (2019)

The Impact of the Magnitude of the Group of Bullies on Health-Related Quality of Life and Academic Performance Among Adolescents
por: Martín-Pérez, Ángela de Lourdes, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_a1b7bdpiu90k57lqi0damri2m9